TARGET AUDIENCE
This educational activity is intended for health care professionals involved in the management of patients with Duchenne muscular dystrophy (DMD), including neurologists and other neuromuscular specialists, as well as pediatric primary care providers and other members of the interprofessional and multidisciplinary teams responsible for the coordinated care of patients with DMD.

PROGRAM OVERVIEW
As advancements in Duchenne muscular dystrophy treatment rapidly evolve, clinicians face growing challenges in staying current. This project aims to bridge that gap by delivering a dynamic, digital resource library designed to equip health care professionals with concise, actionable education. Featuring microlearning formats, the education will address critical knowledge and competence gaps related to therapeutic candidacy, interpretation of the latest clinical data, and tailoring treatment strategies across both ambulatory and non-ambulatory patients of all ages. By empowering clinicians with timely, practical insights, the initiative supports more informed, individualized care for patients with DMD.

Upon completion of this activity, the learners should be able to:

• Evaluate scenarios for patients with DMD to help determine therapeutic candidacy across the age spectrum
• Assess the latest data from clinical studies with DMD treatments to help inform clinical decision-making
• Describe best practices for ongoing monitoring of patients at various ages who are receiving treatment for DMD

FACULTY
Kaitlin Batley, MD
Pediatric Neurologist
UT Southwestern Medical Center
Dallas, TX

Nancy Kuntz, MD
Associate Physician, Division of Neurology
Medical Director, Mazza Foundation Neuromuscular Program
Director, Muscular Dystrophy Associate Care Center
Professor of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine
Ann & Robert Lurie Children’s Hospital of Chicago
Chicago, IL

Samual Mackenzie, MD, PhD
Neurologist
Assistant Professor, Department of Neurology
University of Rochester Medicine
Rochester, NY

Ann Martin, MS, CGC
Vice President, Community Research & Genetic Services
Parent Project Muscular Dystrophy
Washington, DC

Aravindhan Veerapandiyan, MD
Pediatric Neurologist
Assistant Professor of Pediatrics, Division of Pediatric Neurology
Arkansas Children’s Hospital
Little Rock, AR

PLANNING COMMITTEE
Nancy Kuntz, MD
Associate Physician, Division of Neurology
Medical Director, Mazza Foundation Neuromuscular Program
Director, Muscular Dystrophy Associate Care Center
Professor of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine
Ann & Robert Lurie Children’s Hospital of Chicago
Chicago, IL

Aravindhan Veerapandiyan, MD
Pediatric Neurologist
Assistant Professor of Pediatrics, Division of Pediatric Neurology
Arkansas Children’s Hospital
Little Rock, AR

This activity is jointly provided by The France Foundation and Parent Project Muscular Dystrophy.

ACCREDITATION STATEMENT

In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
The France Foundation designates this activity for 1.5 contact hours.

Physician Assistants
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 5/29/26. PAs should only claim credit commensurate with the extent of their participation.

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) requires individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

TFF and PPMD require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and PPMD do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an independent medical educational grant from Sarepta Therapeutics.

The France Foundation and Parent Project Muscular Dystrophy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, Parent Project Muscular Dystrophy, and the commercial supporter(s) assume no liability for the information herein.

Copyright © 2025 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission